New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells.

Angelika Długosz-PokorskaRenata PerlikowskaTomasz JaneckiAnna Janecka

Published in: Biologics : targets & therapy (2023)

Combination of Tx with U-359 reduced overexpression of TUBIII and Nlp. Thus, U-359 may stand for a potential reversal agent for the treatment of MDR in cancer cells.

Keyphrases

multidrug resistant
cell proliferation
breast cancer cells
risk assessment
climate change
replacement therapy